HOME >> MEDICINE >> NEWS
Preliminary study shows high-dose coenzyme Q10 slows functional decline in Parkinson's patients

A national clinical trial with 80 Parkinson's disease patients has shown that high dosages of a naturally occurring compound, coenzyme Q10, slowed by 44 percent the progressive deterioration in function that occurs in the disease. The greatest benefit was seen in everyday activities such as feeding, dressing, bathing and walking.

The study's coordinators caution that while encouraging, the therapy needs to be tested in a larger trial with hundreds of patients before this treatment can be recommended.

Published in the Oct. 15, 2002 issue of the American Medical Association's Archives of Neurology, the study was conducted at 10 sites by the Parkinson Study Group, under the direction of principal investigator Clifford Shults, M.D., professor of neurosciences, University of California, San Diego (UCSD) School of Medicine, and chief of the Neurology Service at the VA San Diego Healthcare System. Parkinson's disease is a degenerative disorder of the brain in which patients develop tremor, slowness of movement and stiffness of muscles. It affects approximately 1 percent of Americans over the age of 65. Although certain drugs, such as levodopa, can reduce the symptoms of Parkinson's disease, no treatment has been shown to slow the progressive deterioration in function.

The selection of coenzyme Q10 as a potential treatment for Parkinson's was based on work carried out over the past decade by Shults, Richard Haas, M.D., UCSD professor of neurosciences, and Flint Beal, M.D., professor and chair of neurology, Weill Medical College of Cornell University.

Shults explained that mitochondria produce the energy-containing molecules that supply energy to chemical reactions in cells and that coenzyme Q10 plays an integral role in that process. He further explained that coenzyme Q10 is also a potent antioxidant. Over the past several years, research by Shults, Haas and Beal showed that mitochondrial function is impaired in patients with Park
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2002


Page: 1 2 3 4

Related medicine news :

1. Preliminary results are promising in Alzheimers gene therapy trial
2. Preliminary report suggests combination therapy may help treat SARS
3. Preliminary study finds stem cells in blood restore damaged heart muscle
4. Preliminary study suggests endomitriosis could contribute to infertility
5. Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
6. Preliminary Study Proves Centuries Of Herbalists Right About Echinacea
7. ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function
8. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
9. UMaine study looks at infants and chronic nighttime crying
10. Chronic pain treatments more effective when taken together, new study shows
11. UNC study: Most N.C. family practitioners engage in unrecognized community service

Post Your Comments:
(Date:4/27/2015)... Launched by a group of ... consumers a way to connect to top local ... a patent-pending Pick Your Price matching algorithm, clients ... laser hair removal and dermal fillers on days ... in their schedules. This allows clients to take ...
(Date:4/26/2015)... has released a new blog post explaining how to find ... to find low cost auto insurance is by comparing quotes. ... in a simple and convenient way. It is no longer ... prices. All the details are now freely available to anyone ... possible to compare online car insurance quotes on a single ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization in the ... the Asian Indian community in the United States and ... two decades. The India News Network Digest of 1990s ... world with the latest news items from India, the ... Forum Digest, edited and contributed by Sheela Murthy, helped ...
(Date:4/26/2015)... 2015 MidSouth Pain Treatment Center ... Southeast. MidSouth Pain Treatment Center is a comprehensive pain ... Oxford and Jackson, two ambulatory surgery centers in Germantown ... and Cordova locations. , Dr. Michael Steuer , ... medicine to help people, and when I discovered that ...
(Date:4/25/2015)... Washington, D.C. (PRWEB) April 25, 2015 ... for Bangladesh Worker Safety issues the following statement following ... 7.8 earthquake hit Kathmandu, Nepal, resulting in the deaths ... this massive earthquake were felt across Nepal, Bangladesh, India ... to offer my heartfelt condolences to the people of ...
Breaking Medicine News(10 mins):Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:Growing Pains for MidSouth Pain Treatment Center 2
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... , April 23, 2015 Once again, BeaconMedaes ... our commitment to patient safety. BeaconMedaes, priority ... against infectious disease. The next generation Zone ... gas sensors are now mounted in the assembly, allowing ... to open ceiling tiles potentially releasing dust spores and ...
(Date:4/23/2015)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its ... on Thursday, April 30, 2015, after the close of U.S.-based ... officer, will host a conference call to review the results ... (PT). The press release and a live ... a link that is posted on the home page and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
Cached News: